53 completed, 26 recruiting, 21 unknown, 13 active not recruiting. 53 Phase 2, 26 Phase 1, 11 Not applicable, 9 Phase 3, 2 Early Phase 1.
Follow Adrenal Cortex Neoplasms: new trials by email Literature Review of Adrenal Cortex Neoplasms trials Research Report on Adrenal Cortex Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma Surgical resection, Preoperative RT - Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC) | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2026-10-26 | 2026-10-21 |
| Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Carfilzomib - Colorectal Neoplasms, Neoplasms | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 20 | 2026-10-26 | 2026-10-21 |
| Endoscopic Ultrasound-Guided Ethanol Ablation for Aldosterone-Producing Adenoma Endoscopic Ultrasound-Guided Ethanol Ablation - Primary Aldosteronism, Aldosterone-Producing Adenoma | Not applicable | Not yet recruiting | Chongqing Medical University | 30 | 2026-07-15 | 2026-07-14 |
| Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension RFA -radiofrequency ablation, Adrenalectomy - Primary Aldosteronism Due to Conn Adenoma, Radiofrequency Ablation Treatment | Not applicable | Recruiting | University Hospital, Toulouse | 134 | 2026-06-05 | 2026-06-11 |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer Biospecimen Collection, Cabozantinib, Cemiplimab - Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 48 | 2026-02-22 | 2026-09-18 |
| A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer DS9051b - Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Daiichi Sankyo | 40 | 2025-11-04 | 2026-05-22 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer Cemiplimab - Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 31 | 2025-09-18 | 2025-10-06 |
| A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery. Radiation - Radiotherapy, High-risk Localized Adrenocortical Carcinoma | Not applicable | Not yet recruiting | Sun Yat-sen University | 58 | 2025-09-15 | 2025-09-03 |
| PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism 68Ga-pentixafor PET/CT - Primary Aldosteronism, Secondary Hypertension | Not applicable | Recruiting | Seoul National University Hospital | 90 | 2025-06-25 | 2025-06-18 |
| Characterization of the Strasbourg Cohort of Patients With Adrenal Cortex Carcinoma Adrenal Cortical Carcinoma | Recruiting | University Hospital, Strasbourg, France | 60 | 2025-06-10 | 2026-01-13 | |
| Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma Camrelizumab, Apatinib, mitotane - Adrenal Cortical Carcinoma, Adrenal Cortical Cancer | Phase 2 | Recruiting | West China Hospital | 28 | 2025-03-15 | 2025-06-03 |
| Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma Triprolizumab, rodiotherapy - Adrenocortical Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 18 | 2025-03-14 | 2025-04-29 |
| An International Study on Pediatric Patients With Rare Tumors. Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin | Recruiting | Azienda Ospedaliera di Padova | 6250 | 2025-01-25 | 2025-07-18 | |
| Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate - Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma | Phase 2 | Recruiting | Emory University | 21 | 2025-01-15 | 2026-02-18 |
| Adrenal Project: Clinical and Epidemiological Characterization of Adrenocortical Carcinoma in a Brazilian Cohort Carcinoma Adrenal, Carcinoma, Adrenocortical Recurrent | Completed | Latin American Cooperative Oncology Group | 150 | 2024-10-09 | 2026-09-02 | |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI Dostarlimab, Chemotherapy - Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma | Phase 2 | Recruiting | UNICANCER | 120 | 2024-07-23 | 2025-12-02 |
| A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors ADCT-701 - Neuroendocrine Carcinomas, Neuroendocrine Tumors | Phase 1 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-06-17 | 2026-10-16 |
Showing 20 of 133. Sign in to see all of them.
Adrenocortical Carcinoma (94) · Adrenocortical Adenoma (19) · Hyperaldosteronism (18) · Pheochromocytoma (18) · Adrenal Gland Neoplasms (15) · Cushing Syndrome (15) · Carcinoma, Renal Cell (13) · Breast Neoplasms (12) · ACTH Syndrome, Ectopic (11) · Carcinoma, Hepatocellular (11) · Melanoma (11) · Neoplasms (11) · Sarcoma (11) · Carcinoma, Non-Small-Cell Lung (10)
Neoplasms by Site (133) · Endocrine Gland Neoplasms (132) · Endocrine System Diseases (132) · Adrenal Cortex Diseases (131) · Adrenal Gland Diseases (131) · Neoplasms (122) · Adrenal Gland Neoplasms (118) · Neoplasms by Histologic Type (105) · Neoplasms, Glandular and Epithelial (102) · Carcinoma (99) · Adenocarcinoma (97) · Neoplasms, Nerve Tissue (38) · Neoplasms, Germ Cell and Embryonal (37) · Neuroectodermal Tumors (37)
Mitotane (10) · Cisplatin (9) · pembrolizumab (8) · Doxorubicin (6) · Etoposide (5) · Magnetic Resonance Spectroscopy (5) · Nivolumab (5) · Specimen Handling (4) · cabozantinib (4) · Cyclophosphamide (3) · Cytoreduction Surgical Procedures (3) · relacorilant (3) · Adrenalectomy (2) · Biopsy (2) · Corlux (2)
National Cancer Institute (NCI) (20) · Corcept Therapeutics (6) · University of Wuerzburg (6) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (5) · M.D. Anderson Cancer Center (5) · Children's Oncology Group (4) · Seoul National University Hospital (3) · Shanghai Jiao Tong University School of Medicine (3) · St. Jude Children's Research Hospital (3) · University Hospital Padova (3) · Dartmouth-Hitchcock Medical Center (2) · INSYS Therapeutics Inc (2) · Memorial Sloan Kettering Cancer Center (2) · National Institutes of Health Clinical Center (CC) (2) · Novartis Pharmaceuticals (2)
United States (71) · Italy (20) · Germany (16) · China (12) · Canada (11) · France (11) · Netherlands (11) · Australia (9) · South Korea (6) · United Kingdom (6) · Spain (5) · Poland (4) · Czechia (3) · Denmark (3) · Japan (3)
Martin Fassnacht, MD (7) · Alfredo Berruti, MD (3) · Jaydira Del Rivero, M.D. (3) · Andreas G Moraitis, MD (2) · Coleman Gross, MD (2) · Jeremy L Davis, M.D. (2) · Jonathan M Hernandez, M.D. (2) · Massimo Terzolo, MD (2) · Nitya Raj, MD (2) · Vivek Samnotra, MD (2) · A.F. Muller, MD, PhD (1) · Alex A. Adjei, MD, PhD (1)
PMID 22551107, PMID 16172198, PMID 17554118, PMID 20580485, PMID 22997446, PMID 25013998, PMID 25559399, PMID 26507877, PMID 32206838, PMID 34675114, PMID 11745214, PMID 11762335, PMID 14985252, PMID 15867769, PMID 16172456, PMID 16580903, PMID 16670169, PMID 16680602, PMID 1675220, PMID 16895957, PMID 18334586, PMID 18491247, PMID 18506026, PMID 18619560, PMID 18764725, PMID 18824557, PMID 19025987, PMID 19223900, PMID 19494162, PMID 19500762, PMID 19649755, PMID 19851811, PMID 20668036, PMID 21220434, PMID 21246024, PMID 21470991, PMID 21612468, PMID 21718784, PMID 21883349, PMID 22143204, PMID 22156929, PMID 22170717, PMID 22170726, PMID 22189997, PMID 22344233, PMID 22399502, PMID 22466348, PMID 22480131, PMID 22837187, PMID 22964741
U10CA098543 (4), 2016 (2), N01CM00038 (2), U10CA180886 (2), 2009 (1), 2018 (1), 2025 (1), N01CM00070 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1), N01CM62204 (1), N01CM62205 (1), N01CM62207 (1), P30CA015083 (1)